• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Here’s how Omar Ishrak transformed Medtronic into the world’s largest medtech operation

Here’s how Omar Ishrak transformed Medtronic into the world’s largest medtech operation

August 28, 2019 By Brad Perriello

Medtronic CEO Omar Ishrak to step downOmar Ishrak used a series of M&A moves and focus on global markets and value-based care to transform Medtronic (NYSE:MDT) into the world’s largest medical device business in less than a decade.

Ishrak is preparing to retire from the corner office next year ahead of the medtech giant’s mandatory retirement age, to be replaced by longtime lieutenant Geoff Martha. Hired in May 2011, Ishrak doubled annual revenues and added $100 billion to Medtronic’s market cap, according to lead director and Textron CEO Scott Donnelly.

Although early turns toward global markets and value-based healthcare were sustained over the course of his nearly decade-long run, Ishrak will be most widely remembered for the largest-ever medtech merger – the $50 billion buyout of Covidien in early 2015 –  and the raft of other M&A moves that defined his time at Medtronic.

His influence over the company will extend past his last day as CEO on April 26, 2020, when he’s due to assume the newly created executive chairmanship the next day. Apart from having a hand-picked successor take over, his new role entails providing “counsel and guidance to Medtronic’s leadership, oversee CEO succession, and drive the ongoing successful execution of Medtronic’s long-term strategic plan.”

Here’s a closer look at the at least $56.02 billion Medtronic spent on acquisitions under Ishrak’s watch (not to mention the $6.48 billion he brought in by selling company assets):

  • Buys Titan Spine (June 27, 2019, value undisclosed)
  • Buys Epix Therapeutics(June 24, 2019, $316 million)
  • Sells Responsive Orthopedics (May 9, 2019, value undisclosed)
  • Sells stake in LifeTech Scientific(May 7, 2018, value undisclosed)
  • Buys Mazor Robotics (Dec. 19, 2018, $1.7 billion)
  • Buys QT Vascular’s Chocolate PTA (Jan. 30, 2018, $28 million)
  • Buys Crospon(Dec. 11, 2017, $45 million)
  • Sells patient care business (July 31, 2017, $6 billion)
  • Buys HeartWare (August 23, 2016, $1 billion)
  • Buys Smith & Nephew’s Truclear (August 8, 2016, $350 million)
  • Buys Responsive Orthopedics( June 8, 2016, value undisclosed)
  • Buys Bellco( Feb. 1, 2016, value undisclosed)
  • Buys Baylis Medical’s OsteoCool (Jan. 13, 2016, value undisclosed)
  • Buys Aircraft Medical (Nov. 18, 2015, $110 million)
  • Buys Twelve Inc. (Oct. 5, 2015, $458 million)
  • Buys Lazarus Effect (Sept. 28, 2015, $100 million)
  • Buys Medina Medical (Sept. 1, 2015, $150 million)
  • Buys RF Surgical Solutions (July 13, 2015, $235 million)
  • Buys Aptus Endo (June 19, 2015, $110 million)
  • Buys CardioInsight (June 19, 2015, $93 million)
  • Buys Diabeter (April 2, 2015, avlue undisclosed)
  • Buys Sophono (March 26, 2015, value undisclosed)
  • Buys Covidien (Jan. 26, 2015, $50 billion)
  • Buys NGC MedicalAugust 27, 2014, $350 million)
  • Sells Pillar Palatal (Feb. 14, 2014, value undisclosed)
  • Buys Tyrx (Jan. 6, 2014, $160 million)
  • Buys China Kanghui Holdings (Nov. 1, 2012, $816 million)
  • Sells Physio-Control (Jan. 30, 2012, $478 million)

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: Medtronic, Personnel Moves

More recent news

  • Massachusetts Life Sciences Center offers grants to lower medtech commercial risk
  • The 10 largest medical device companies
  • CSL to drop Terumo for Haemonetics in US plasma collection supply deal
  • How 5 medtech CEOs design for access
  • Butterfly Network to chase ultrasound brain-computer interfaces with newcomer Bridge Neurotech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy